Pilot Study of Effects of Bazedoxifene plus Conjugated Estrogen on Imaging and Blood Biomarkers In Women with Menopausal Symptoms at Increased Risk for Breast Cancer

This cancer prevention trial based at the University of Kansas Medical Center is an RO1 study funded by the National Cancer Institute. This study is active, but not currently recruiting. 

PI: Carol Fabian, M.D. Kimler, Nye, Winblad co-I.

Learn more at ClinicalTrials.gov (Identifier: NCT04821375)

Phase IIA Trial of Acolbifene 20 mg vs Low Dose Tamoxifen 5 mg in Pre-menopausal Women at High Risk for Development of Breast Cancer

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. Funded by the National Cancer Institute via a subcontract from the University of Michigan Early Phase Consortium. This study is actively recruiting.

PI: Carol Fabian, M.D. 

Learn more at ClinicalTrials.gov (Identifier: NCT05941520)

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women with Obesity and Other Risk Factors for Breast Cancer

This cancer prevention trial focuses on the evaluation of biomarkers for the risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss. Dr. Carol Fabian, PI. Cathleen Beaver, M.D., co-PI of the clinical protocol. This study is actively recruiting women age 40-64 with a BMI ≥30 and at least 1 risk factor for breast cancer in addition to obesity.

PI: Carol Fabian, M.D.

Learn more at ClinicalTrials.gov (Identifier: NCT06485089)

Low-Dose Tamoxifen with or without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Funded by the National Cancer Institute via a subcontract from the University of Michigan Early Phase Consortium. This study is not yet recruiting.

PI: Lauren Nye, M.D. Carol Fabian, M.D., co-PI (mentor).

Learn more at ClinicalTrials.gov (Identifier: NCT06195306)

Project BRA (Breast cancer Risk Assessment): A Community-Engaged Approach to Develop Partnerships with Trusted Healthcare Providers of Black and African American Women in Areas with High Breast Cancer Mortality Rates

Funded by a KU Cancer Center Health Equity Pilot Grant.

PI: Lauren Nye, M.D.

A Phase IIb Clinical Trial of the Multitargeted Recombinant Adenovirus 5 CEA/MUC1/Brachyury Vaccines Tri-Ad5 and IL-15 Superagonist N-803 in Lynch syndrome

Dr. Ajay Bansal, a world expert in Barrett’s esophagus, serves as national PI for this Lynch syndrome vaccine trial, which tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. This trial is actively recruiting.

PI: Ajay Bansal, M.D.

Learn more at ClinicalTrials.gov (Identifier: NCT05419011)

Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico

Jeffrey Weitzel, M.D., co-authored this study on the development and pilot implementation of hte GRACIAS intervention in Mexico, published in JCO Global Oncology.